Revenue
2025
Oaktree Acquisition Corp. III Life Sciences (OACC)
Price$10.77Cached quote
Net income
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2024
2025
Financial statements
| 2025 | |
|---|---|
| Revenue | $0 |
| Operating expenses | $1.2M |
| Operating income | −$1.2M |
| EBITDA | −$1.2M |
| Net income | $7.3M |
| Basic EPSper basic share | $0.30 |
| Diluted EPSper diluted share | $0.30 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
AQR Arbitrage LLC | 1.32M |
Fort Baker Capital Management LP | 1.11M |
Decagon Asset Management LLP | 1.09M |
Empyrean Capital Partners, LP | 900K |
D. E. Shaw & Co., Inc. | 861.63K |
BOUSSARD & GAVAUDAN GESTION SAS | 720K |
Linden Advisors LP | 600K |
TORONTO DOMINION BANK | 554.29K |
Sculptor Capital LP | 530.81K |
GOLDMAN SACHS GROUP INC | 529.54K |
MOORE CAPITAL MANAGEMENT, LP | 525K |
LMR Partners LLP | 510.9K |
Alberta Investment Management Corp | 500K |
Verition Fund Management LLC | 470.34K |
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 450K |
Ghisallo Capital Management LLC | 450K |
TWO SIGMA INVESTMENTS, LP | 437.5K |
GRITSTONE ASSET MANAGEMENT LLC | 394.91K |
Radcliffe Capital Management, L.P. | 387.22K |
K2 PRINCIPAL FUND, L.P. | 365.9K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data